

Atypical Infections While Being Treated with a JAK Inhibitor: Significance and Management

Time	Question
00:58	How worried should we be about atypical infections in patients on a JAK2 inhibitor therapy?
06:17	Do we have any sense that the infections are more severe in these patients or that they are related to the duration of the therapy or exposure to JAK inhibitors?
08:45	Do we need to interrupt therapy or judge it based on our medical knowledge? Should we use vaccinations more regularly to reduce infections?
11:32	Do you recommend the Herpes Zoster Vaccine or are you unsure about recommending that vaccine?
13:38	How is the possible influence of the Ruxolitinib, JAK 1, JAK2, and atypical infections affecting the eligibility or outcome of transplant?
15:03	Is the possible theoretical risk precluding you from transplanting patients on a JAK2 inhibitor or are you worried about something going wrong?
17:40	Are people doing routine PPD testing before initiating JAK inhibitor therapy?